Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

Paulette Mhawech-Fauceglia, Dan Wang, Damanzoopinder Samrao, Heidi Godoy, Faith Ough, Song Liu, Tanja Pejovic, Shashikant Lele

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalGynecologic Oncology
Volume127
Issue number1
DOIs
StatePublished - Oct 2012

Fingerprint

Carcinoma
Proteins
Recurrence
Survival
Ovarian Neoplasms
Small Interfering RNA
Neoplasms
Cell Survival
Transcription Factors
Biomarkers
Immunohistochemistry
Cell Line
Therapeutics

Keywords

  • Disease outcome
  • Immunoexpression
  • Ovarian serous cancer
  • PAX8

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Mhawech-Fauceglia, P., Wang, D., Samrao, D., Godoy, H., Ough, F., Liu, S., ... Lele, S. (2012). Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecologic Oncology, 127(1), 198-201. https://doi.org/10.1016/j.ygyno.2012.06.012

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. / Mhawech-Fauceglia, Paulette; Wang, Dan; Samrao, Damanzoopinder; Godoy, Heidi; Ough, Faith; Liu, Song; Pejovic, Tanja; Lele, Shashikant.

In: Gynecologic Oncology, Vol. 127, No. 1, 10.2012, p. 198-201.

Research output: Contribution to journalArticle

Mhawech-Fauceglia, Paulette ; Wang, Dan ; Samrao, Damanzoopinder ; Godoy, Heidi ; Ough, Faith ; Liu, Song ; Pejovic, Tanja ; Lele, Shashikant. / Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. In: Gynecologic Oncology. 2012 ; Vol. 127, No. 1. pp. 198-201.
@article{595c0ca413b04b8a8122f0839330e201,
title = "Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma",
abstract = "Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61{\%} of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.",
keywords = "Disease outcome, Immunoexpression, Ovarian serous cancer, PAX8",
author = "Paulette Mhawech-Fauceglia and Dan Wang and Damanzoopinder Samrao and Heidi Godoy and Faith Ough and Song Liu and Tanja Pejovic and Shashikant Lele",
year = "2012",
month = "10",
doi = "10.1016/j.ygyno.2012.06.012",
language = "English (US)",
volume = "127",
pages = "198--201",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma

AU - Mhawech-Fauceglia, Paulette

AU - Wang, Dan

AU - Samrao, Damanzoopinder

AU - Godoy, Heidi

AU - Ough, Faith

AU - Liu, Song

AU - Pejovic, Tanja

AU - Lele, Shashikant

PY - 2012/10

Y1 - 2012/10

N2 - Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.

AB - Objectives: Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC. Methods: PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS). Results: We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome. Conclusion: Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy.

KW - Disease outcome

KW - Immunoexpression

KW - Ovarian serous cancer

KW - PAX8

UR - http://www.scopus.com/inward/record.url?scp=84865699113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865699113&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2012.06.012

DO - 10.1016/j.ygyno.2012.06.012

M3 - Article

VL - 127

SP - 198

EP - 201

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -